Abstract
Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH. The present study aimed to verify the effect of MET in functional EH and polycystic ovary syndrome (PCOS). H&E staining was performed to analyze the severity of EH, and immunohistochemistry was performed to evaluate the expression of GLUT4 in the endometrium of PCOS rats. Reverse transcription‑quantitative PCR was used to calculate the expression of long non‑coding (lnc)RNA‑maternally expressed gene 3 (MEG3), lncRNA‑small nucleolar RNA host gene 20 (SNHG20), GLUT4 mRNA, microRNA (miR)‑223 and miR‑4486. Sequence analysis and luciferase assays were performed to explore the regulatory relationship among certain lncRNAs, miRNAs and target genes. EH in PCOS rats was efficiently inhibited by MET administration. The increased expression of GLUT4 in PCOS rats was attenuated by MET treatment. Moreover, the expression levels of lncRNA‑MEG3 and lncRNA‑SNHG20 were significantly inhibited in the endometrium of PCOS rats. MET treatment also showed remarkable efficiency in restoring the expression of lncRNA‑MEG3 and lncRNA‑SNHG20. Meanwhile, the expression levels of miR‑223 and miR‑4486 were notably elevated in the endometrium of PCOS rats, while MET treatment reduced the expression of miR‑223 and miR‑4486 in PCOS rats. Furthermore, a luciferase assay confirmed the inhibitory relationship between miR‑223 and lncRNA‑MEG3/GLUT4 expression, as well as between miR‑4486 and lncRNA‑SNHG20/GLUT4 expression. GLUT4 knockdown restored the decreased viability of HCC‑94 cells induced by overexpression of lncRNA‑MEG3. To conclude, MET exhibited a therapeutic effect in the treatment of EH by modulating the lncRNA‑MEG3/miR‑223/GLUT4 and lncRNA‑SNHG20/miR‑4486/GLUT4 signaling pathways. This work provides mechanistic insight into the development of EH.